{"id":9527,"date":"2026-02-07T12:18:09","date_gmt":"2026-02-07T09:18:09","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9527"},"modified":"2026-02-07T12:18:09","modified_gmt":"2026-02-07T09:18:09","slug":"dyslipidemia-back-in-focus","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/dyslipidemia-back-in-focus\/","title":{"rendered":"Dyslipidemia back in focus"},"content":{"rendered":"<div>Dyslipidemia back in focus<\/div>\n<div><\/div>\n<div><span> \u2022 New ESC\/EAS focused update (2025) is influencing upcoming AHA\/ACC guidelines expected in early 2026.<\/span><\/div>\n<div><span> \u2022 Major advances since the last US update in 2019 support lower LDL-C targets in high-risk patients.<\/span><\/div>\n<div><span> \u2022 Updated risk assessment tools: SCORE2\/SCORE2-OP in Europe; AHA PREVENT in the US.<\/span><\/div>\n<div><span> \u2022 Screening \u2014 when?<\/span><\/div>\n<div><span> \u2022 Start at age 20 for routine lipid screening.<\/span><\/div>\n<div><span> \u2022 Earlier only if high risk (strong family history, suspected familial hypercholesterolemia).<\/span><\/div>\n<div><span> \u2022 Repeat every 4\u20136 years if low risk; more often if risk is present.<\/span><\/div>\n<div><span> \u2022 Greater emphasis on risk enhancers, including:<\/span><\/div>\n<div><span> \u2022 Lp(a) elevation<\/span><\/div>\n<div><span> \u2022 CAC (coronary artery calcium score on CT) indicating subclinical atherosclerosis<\/span><\/div>\n<div><span> \u2022 Chronic kidney disease (CKD)<\/span><\/div>\n<div><span> \u2022 Pregnancy-related risk (history of preeclampsia, gestational hypertension or diabetes, premature menopause)<\/span><\/div>\n<div><span> \u2022 Family history of premature ASCVD<\/span><\/div>\n<div><span> \u2022 Evidence supports earlier and sustained LDL-C lowering, including initiation during ACS hospitalization.<\/span><\/div>\n<div><span> \u2022 In patients with subclinical CAD, treatment targets often aim for LDL-C &lt;55 mg\/dL within a high-risk primary prevention framework; aspirin is not routinely recommended as primary prevention and should be considered only in selected patients with CAC \u2265400 and low bleeding risk.<\/span><\/div>\n<div><span> \u2022 Recognition that LDL-C alone may underestimate risk in metabolic syndrome.<\/span><\/div>\n<div><span> \u2022 Bempedoic acid endorsed for select patients, particularly statin-intolerant individuals, with cost and safety considerations (uric acid\/gout).<\/span><\/div>\n<div><span> \u2022 Lp(a) testing recommended at least once in a lifetime for improved risk stratification.<\/span><\/div>\n<div><\/div>\n<div>Source: Medscape Medical News<\/div>\n<div>Date: February 05, 2026<\/div>\n<div>\ud83d\udd17 <a href=\"https:\/\/www.medscape.com\/viewarticle\/dyslipidemia-recent-research-prompts-new-guidance-2026a10003o7\">https:\/\/www.medscape.com\/viewarticle\/dyslipidemia-recent-research-prompts-new-guidance-2026a10003o7<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dyslipidemia back in focus \u2022 New ESC\/EAS focused update (2025) is influencing upcoming AHA\/ACC guidelines expected in early 2026. \u2022 Major advances since the last US update in 2019 support lower LDL-C targets in high-risk patients. \u2022 Updated risk assessment tools: SCORE2\/SCORE2-OP in Europe; AHA PREVENT in the US. \u2022 Screening \u2014 when? \u2022 Start [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9527","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9527"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9527\/revisions"}],"predecessor-version":[{"id":9528,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9527\/revisions\/9528"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}